Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-12-19
2008-03-11
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S290000, C544S361000, C546S093000
Reexamination Certificate
active
07342016
ABSTRACT:
Disclosed are novel tricyclic compounds represented by the formula (1.0):and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
REFERENCES:
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5151423 (1992-09-01), Piwinski et al.
patent: 5393890 (1995-02-01), Syoji et al.
patent: 5416087 (1995-05-01), Wong et al.
patent: 5696121 (1997-12-01), Bishop et al.
patent: 5714609 (1998-02-01), Doll et al.
patent: 5719148 (1998-02-01), Bishop et al.
patent: 5721236 (1998-02-01), Bishop et al.
patent: 5728703 (1998-03-01), Bishop et al.
patent: 5861395 (1999-01-01), Taveras et al.
patent: 5874442 (1999-02-01), Doll et al.
patent: 5925648 (1999-07-01), Cooper et al.
patent: 6071907 (2000-06-01), Njoroge et al.
patent: 6075025 (2000-06-01), Bishop et al.
patent: 2005/0059672 (2005-03-01), Zhu et al.
patent: 0270818 (1987-10-01), None
patent: 0 988 300 (2002-08-01), None
patent: WO94/24107 (1994-10-01), None
patent: WO95/10516 (1995-04-01), None
patent: WO96/30363 (1996-10-01), None
patent: WO97/02348 (1997-01-01), None
patent: WO98/11092 (1998-03-01), None
patent: WO98/57948 (1998-12-01), None
patent: WO98/57949 (1998-12-01), None
patent: WO98/57960 (1998-12-01), None
patent: WO 00/37458 (2000-06-01), None
patent: WO 00/37459 (2000-06-01), None
patent: WO 01/56552 (2001-08-01), None
patent: WO 02/18368 (2002-03-01), None
Kaminski et al. “Identification of Novel Farnesyl Protein Transferase Inhbitiors using three-dimensional database searching methods,” J. Med. Chem 1997, 40, pp. 4103-4112.
PCT International Search Report dated Feb. 5, 2002 for corresponding PCT Application No. PCT/US01/26792.
PCT International Search Report dated Aug. 4, 2003 for corresponding PCT Application No. PCT/US03/05479.
Mallams, A.K. et al., Inhibitors of Farnesyl Protein Transferase, 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]-cycloheptal[1,2-b]pyridine-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11 dihydro-5H-benzo[5,6]cycloheptal[1,2-b]pyridine-11-yl)piperazine,Journal of Medicinal Chemistry41(6):877-893 (1998).
Njoroge, F.G. et al., Potent, Selective, and Orally Bioavailable Tricyclic Pyridyl Acetamide N-Oxide Inhibitors of Farnesyl Protein Transferase with Enhanced in Vivo Antitumor Activity,J. Med. Chem. 41(10):1561-1567 (1998).
Schering-Plough Discontinues Phase III Clinical Study of Sarasar(TM) (Lonafarnib) in Non-Small-Cell Lung Cancer, Schering-Plough Press Release, Feb. 5, 2004.
Alvarez Carmen S.
Baldwin John J.
Cooper Alan B.
Desai Jagdish A.
Doll Ronald J.
Jeanette Henry C.
Pharmacopeia Inc.
Sackey Ebenezer
Schering Corporation
Wilson James O.
LandOfFree
Farnesyl protein transferase inhibitors as antitumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Farnesyl protein transferase inhibitors as antitumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesyl protein transferase inhibitors as antitumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965316